|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Circadian variation in pain onset in unstable anginapngina pectoris显示文摘 | BEHAR S REICHER-REISS H GOLDBOURT U | 1991 | Am J Cardiol1991，67，1： | 2 |
| 2 | Trends in Management and Outcome of Hospitalized Patients With Acute Stroke and Transient Ischemic Attack: The National Acute Stroke Israeli (NASIS) Registry显示文摘 | David Tanne Silvia Koton Noa Molshazki Uri Goldbourt Tamar Shohat Rakefet Tsabari Ehud Grossman Natan M. Bornstein | 2012 | Stroke2012，，： | 2 |
| 3 | CAD患者治疗时血清高密度脂蛋白胆固醇水平增量与心脏性死亡的关系:来自苯扎贝特心肌梗死预防试验显示文摘This study evaluated the association between changes in serum levels of high- density lipoprotein(HDL) cholesterol that occur under bezafibrate therapy and cardiac mortality in patients with coronary heart disease(CHD) who were enrolled in the Bezafibrate Infarction Prevention trial. We compared serum levels of HDL cholesterol in 1,509 patients in tertiles of on- treatment increments with those of 1,517 patients in the placebo group. Long- term follow- up showed that cardiac mortality decreased significantly with increasing tertiles of on- treatment change in HDL cholesterol(9.5% , 6.6% , and 6.3% of patients tertiles 1, 2, and 3, respectively, died of cardiac causes, p for trend=0.02). In multivariate analysis, the magnitude of on- treatment increment of HDL cholesterol was independently associated with a decreased risk of cardiac death(hazard ratio 1.05, 95% confidence interval 0.74 to 1.47, for tertile 1; hazard ratio 0.73, 95% confidence interval 0.50 to 1.07, for tertile 2; hazard ratio 0.65, 95% confidence interval 0.43 to 0.97, for tertile 3, compared with placebo- allocated patients, p for trend=0.02). Analyzing the association with change in HDL cholesterol as a continuous variable showed that the risk of cardiac mortality was decreased by 27% for every 5- mg/dl increase in on- treatment change in HDL cholesterol(p< 0.001). In conclusion, although a definite secondary prevention effect of bezafibrate could not be found when examining the intervention group as a whole, our findings are consistent with a possible independent association between an increase in HDL cholesterol with bezafibrate therapy and a decrease in cardiac mortality. In appropriately selected patients, monitoring short- term response to bezafibrate therapy through change in HDL cholesterol may indicate the potential long- term benefit of the drug. | Goldenberg I. Goldbourt U. Boyko V. 姜朝晖 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，6： | 2 |
| 4 | Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patients显示文摘 | Morag-Koren N Goldbourt U | 2004 | Hypertens2004，22，3： | 1 |
| 5 | Antihypertensive therapy in :liabetic hypertensive patients显示文摘 | Messerli FH Grossman E Goldbourt U | 2001 | Am J Hypertens2001，14，： | 1 |
| 6 | Association between serum apoli- poprotein C( Ⅱ ) concentration and coronary heart disease 显示文摘 | Gerber Y Goldbourt U Cohen H | 2002 | PrevMed2002，35，1： | 1 |
| 7 | Uric acid and diabetes: observa- tions in a population study显示文摘 | Herman JB Goldbourt U | 1982 | Lancet1982，2，8292： | 1 |
| 8 | Blood lipids and first- ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high tfiglycefides constitute an independent risk factor显示文摘 | Tanne D Koren - Morag N Graft E Goldbourt U | 2001 | Circulation2001，104，24： | 1 |
| 9 | Relation between the metabolic syndrome and ischemic stroke or transient ischemie attack: a prospective cohort study in patients with atheroselerotic cardiovascular disease 显示文摘 | Koren-Morag N Goldbourt U Tanne D | 2005 | Stroke2005，36，7： | 1 |
| 10 | Aspirin and mortality in patients treated with angiotensin-coverting enzyme inhibitors: a cothort study of ll,575 patients with coronary artery disease显示文摘 | Leor J Reicher-Reiss H Goldbourt U Boyko V Gottlieb S Battler A | 1999 | J Am Coll Cardiol1999，33，： | 1 |
| 11 | Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease显示文摘 | Dankner R Goldbourt U Boyko V | 2003 | Am J Cardiol2003，91，2： | 1 |
| 12 | Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease 显示文摘 | KOREN-MORAG N GOLDBOURT U TANNED | 2006 | Neurology2006，67，2： | 1 |
| 13 | C-reactive protein as a predictor of incident Isehemic stroke among patients with preexisting cardiovascular disease显示文摘 | Tanne D Benderly M Goldbourt U | 2006 | Streke2006，37，7： | 1 |
| 14 | Fast ing plasma glucose and risk of incident ischemic stroke or transient ischemic attacks : a prospective cohort study 显示文摘 | Tanne D Koren-Morag N Goldbourt U | 2004 | Stroke2004，35，： | 1 |
| 15 | Fasting plasma glucose and risk of incident ischemie stroke or transient isehemic attacks : a pro- speetive cohort study 显示文摘 | Tanne D Koren-Morag N Goldbourt U | 2004 | Stroke2004，35，： | 1 |
| 16 | Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease显示文摘 | Dankner R Goldbourt U Boyko V | 2003 | Am J Cardiol2003，91，2： | 1 |
| 17 | Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack:a prospective cohort study in patients with atherosclerotic cardiovascular disease 显示文摘 | Koren-Morag N Goldbourt U Tanne D | 2005 | Stroke2005，36，7： | 1 |
| 18 | High blood pressure anddiabetes mellitus:are all antihypertensive drugs created equal?显示文摘 | Grossman E Messerli FH Goldbourt U | 2000 | Arch Intern Med2000，60，6： | 1 |
| 19 | Is serum uric acid level an independent predictor of heart failure among patients with coronary artery disease显示文摘 | Eisen A Benderly M Goldbourt U | 2013 | Clin Cardiol2013，36，2： | 1 |
| 20 | Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks:a prospective cohort study显示文摘 | Tanne D Koren-Morag N Goldbourt U | 2004 | Stroke2004，35，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员